IBM is unleashing Watson on healthcare. The tech heavyweight's brand-new healthcare business unit says it will team up with 14 top cancer centers to turn genetic data into personalized patient treatments.
Eli Lilly will open a new drug delivery and device innovation center in Cambridge, MA. Medical devices aren't a focus for the pharma now--but it noted that more than half of its current pipeline candidates are biologics that require injection. It expects to double its revenues from device-enabled products by 2020 and is looking to have a hand in that arena.
Eli Lilly is the latest multinational drugmaker looking to Cambridge, MA, to jump-start its innovation engine, blueprinting a new R&D outpost on the Charles River as biotech's hippest neighborhood gets more and more crowded.
Cytomegalovirus (CMV) presents no symptoms in most healthy people, but it can be life-threatening in people with weakened or underdeveloped immune systems. So City of Hope and Fortress Biotech have joined the race to produce vaccines to control CMV infections.
After striking out in a solo IPO attempt, Tobira Therapeutics has executed a reverse merger with the stalled Regado Biosciences, raising $40 million to target a pervasive liver disease.
Close to 5 years after GlaxoSmithKline signed on to collaborate with the San Raffaele Telethon Institute for Gene Therapy in Italy, the partners have stepped up with a European application to start marketing a gene therapy for extraordinarily rare cases of immune deficiency triggered by ADA-SCID. And its delivery into regulatory hands comes as the gene therapy field has been recoiling from some notable setbacks that have begun to cloud what has been a bullish sector in biotech.
Cancer drug pricing is turning more and more heads, especially as critical payers threaten a crackdown in the oncology field. And there's a reason for all the hullaballoo: Spending on oncology meds is increasing rapidly, new IMS numbers show.
As the med tech industry targets innovative technologies to treat orthopedic injuries, scientists are developing artificial knee implants that could help ward off arthritis and surgery further down the road.
The U.S. National Institutes of Health's National Eye Institute is spending up to $17.9 million over the next 5 years to find new therapies for blindness. In addition, the NIH just unveiled its Alzheimer's disease research agenda.
At its investor day on May 1, Boston Scientific pledged to accelerate sales growth to 3% to 6% and boost its operating margins to 25% by 2017 on the back of a promising product pipeline, like the newly approved Watchman device for preventing stroke and the next generation of its fast selling S-ICD, which reduces implantable defibrillators' reliance on troublesome wires known as leads.